Ally Bridge Group »

89bio shares owned by Ally Bridge Group

Quarter-by-quarter ownership of 89bio (ETNB) shares owned by Ally Bridge Group from 13F filings

Historical chart of Ally Bridge Group investment in 89bio

Tip: Access up to 7 years of quarterly data

All positions including 89bio held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 89bio by Ally Bridge Group

Quarter filed Position value Share count Share price at filing
2024-12-31 $2.5M 318k 7.82

More positions owned by Ally Bridge Group

Soleno Therapeutics (SLNO)
Replimune Group Call Option (REPL)
Madrigal Pharmaceuticals (MDGL)
Compass Pathways Sponsored Ads (CMPS)
Atai Beckley Nv SHS (ATAI)
Ascendis Pharma A/s - Sponsored Adr (ASND)
Lenz Therapeutics (LENZ)
Taysha Gene Therapies Com Shs (TSHA)
Amylyx Pharmaceuticals (AMLX)
Eupraxia Pharmaceuticals (EPRX)
Praxis Precision Medicines I Com New Call Option (PRAX)
Monopar Therapeutics Com New (MNPR)
Arcutis Biotherapeutics (ARQT)
Mind Medicine Mindmed Com New (MNMD)
Tarsus Pharmaceuticals (TARS)

View all positions for Ally Bridge Group

Top funds holding 89bio

RA Capital Management
Pentwater Capital Management
BlackRock
Deep Track Capital
Adage Capital Partners GP
Suvretta Capital Management
Vanguard Group
venBio Select Advisor
Glazer Capital
Henderson Group
State Street Corporation
Deutsche Bank Aktiengesellschaft
Westfield Capital Management Company
Geode Capital Management
LMR Partners

View all funds holding 89bio